Is Lannett Going Out Of Business: Current Status Explained

Thinking about whether Lannett is going out of business? You might have seen headlines about bankruptcy, restructuring, and stock cancellations. The reality is more nuanced—and useful to understand if you’re a business builder or curious about the pharmaceutical industry.

Here’s the current situation: Lannett isn’t going out of business. The company faced tough financial times, went through Chapter 11 bankruptcy, and is now part of a new ownership group. If you want practical, plain-English answers—whether you’re an investor, customer, or teammate—keep reading for step-by-step clarity.

Start by Understanding Chapter 11 Bankruptcy: What Happened?

Let’s begin with the basics. Chapter 11 bankruptcy isn’t the same as shutting down; it’s a structured legal process companies use to reorganize debt and keep their business alive, not to liquidate assets and disappear.

In Lannett’s case, the company:

• Announced a “prepackaged” Chapter 11 bankruptcy—this means the company and its key creditors agreed on a plan before filing in court.
• Filed for bankruptcy protection to cut about $597 million in debt and boost cash flow for current and future products.
• Got court approval for its plan on June 8, 2023, and quickly emerged as a restructured and privately held company.

Key takeaway: The “old” Lannett Company, Inc. (the public stock you could once buy) is gone, but the business itself continues. If you’re mapping out business risks, this process is sometimes called a “balance sheet fix.”

Transitioning to Private Ownership: What Changed?

Ask yourself: Why does it matter if a business is public or private? For most customers and employees, it doesn’t—what matters is whether the company is still shipping products and paying the bills.

After the bankruptcy process:

• Lannett stopped trading as a public company—all previous common stock shares were canceled.
• The company is now privately owned by its former secured creditors (the lenders who had first claim on company assets).
• The core management team, including CEO Tim Crew, remained in place. The board slimmed down to three members.

Checklists can help founders understand this type of transition:

• Is the core business model intact? Yes—Lannett continues to make and distribute drugs.
• Are operations ongoing? Yes, from U.S. facilities in Pennsylvania and Indiana.
• Are shareholders affected? Yes—all public shares are wiped out (more in a bit).

Tip: In business, ownership changes often look dramatic from the outside, but for employees and customers, the day-to-day work remains similar.

Lannett’s Operations: What’s Actually Happening Now?

The question for any operator is: “Are they still delivering?” For Lannett, the answer is yes.

Here are the facts:

• Lannett describes itself as a leading generic pharmaceutical manufacturer with an active portfolio of over 100 product families.
• The company maintains manufacturing, research, and distribution hubs, employing hundreds of people across Pennsylvania and Indiana.
• Its core focus remains on affordable, life-enhancing medicines, including generic insulin, respiratory drugs, and ADHD treatments.

Did you know? The average generic drug company makes money on scale and efficiency, not flashy new inventions. Lannett’s restructuring cut debt, giving the business more breathing room to handle R&D and supply chain needs.

Key takeaway: Lannett is surviving—not closing its doors or laying off entire workforces.

Lannett’s Next Chapter: Acquisition by Aurobindo Pharma

If you’re tracking company exits or M&A trends, watch this sequence:

• Aurobindo Pharma, a global pharmaceutical company, decided to acquire Lannett Company Inc. for $250 million.
• The FTC (Federal Trade Commission) reviewed the deal and required several generic products to be divested to ensure market competition.
• After clearing regulatory hurdles, the acquisition closed in late June 2026.

So what changed?

• Lannett is now a wholly owned subsidiary of Aurobindo Pharma USA, Inc.
• The business now operates as Lannett Company LLC.
• Aurobindo highlighted Lannett’s strength in complex generics, including DEA-controlled substances (think certain pain or ADHD drugs).
• Commitments were made to maintain steady access and integration, preventing disruptions for pharmacies or customers.

If you’re studying business combinations, this is a classic example of an ongoing business being “absorbed” by a market peer—not vanishing.

Investor Reality Check: What Happened to Lannett Stock?

If you’re an investor or thinking of investing, this is the part where you need to read carefully.

Here’s exactly what happened:

• When Lannett filed for Chapter 11, all public shares became worthless. The equity was canceled.
• No shares of Lannett Company, Inc. have traded since; there is no stock ticker or public float any longer.
• Ownership was transferred to previous lenders (the creditors), then, after the acquisition, to Aurobindo and its investors.

Key advice: Don’t be fooled by online rumors or tips suggesting “hidden value” in old shares. Bankruptcy wipes out public equity as part of the formal court process. Any future value now goes to Aurobindo and its shareholders only.

If you want to understand how bankruptcy works for investors, study simple case studies like this before you risk your own money.

Legal Hurdles Resolved: Compliance and Moving On

Companies in generic pharmaceuticals often face regulatory and legal scrutiny. Lannett was no exception.

Here’s what happened:

• Lannett was accused by multiple states of participating in conspiracies to inflate prices and stifle competition in the generic drug market.
• The company settled these lawsuits, agreeing to pay fines and create internal processes to comply with antitrust laws.

Actionable reminder:

• Legal risk is real and can derail a business.
• Lannett’s issues led to reforms and settlements, not forced closure or criminal shutdown.
• If you’re building a regulated business, prioritize compliance before regulators prioritize you.

This shouldn’t scare you off, but it’s a good reminder: Attention to legal basics saves you grief in the long run.

How Does This Affect You? Practical Perspectives

Let’s break it down depending on your role:

For patients and pharmacies:

• Lannett’s products—especially affordable generic drugs—will continue reaching shelves. The company’s new ownership by Aurobindo aims to ensure uninterrupted supply and compliance.

For employees and business partners:

• The daily work continues. Integration with Aurobindo is already underway, with promises of operational stability. Look for updates about HR, benefits, or contracts from your new corporate parent.

For investors or stock-watchers:

• The Lannett ticker is gone—your equity claim now belongs to history. Any future value accrues to Aurobindo shareholders and leadership. Always verify a stock exists before trading or following.

If you’re curious about other cases where public companies disappear but operations survive, you can find guides at Sunrise Clicks.

Tip: Are you considering buying into businesses in regulated industries? Always check the company’s balance sheet, legal history, and what happens to equity in a bankruptcy. The formula is simple: If liabilities exceed assets—and lenders take over—equity gets zeroed out.

Conclusion: Is Lannett Going Out of Business?

So, is Lannett going out of business? No—the operating company survived its financial storm, reorganized under bankruptcy, and was acquired by Aurobindo Pharma USA in 2026.

What’s changed?

• The old public stock is gone.
• The business is private and owned by a larger, global pharmaceutical group.
• Operations, jobs, and product lines continue—often with better financial health thanks to debt restructuring.

Before you worry about any business “disappearing” during a bankruptcy or sale, ask yourself: Is the core product still being made or service still provided? If yes, the business is surviving, even if the sticker on the ownership changes.

Key takeaway: In regulated, product-driven businesses like pharmaceuticals, a company can “die” as a public stock but thrive as a private operation under new hands. When analyzing any business—ask who owns the assets today and how customers are being served. Stay practical. Helping you make informed, low-drama business decisions is the real goal.

Read Also This:

• Is Eblens Going Out of Business